|
|
|||||||
Platelets |
From the Clinical Research Center, Thrombosis and Hemostasis Research Group of the Hungarian Academy of Sciences (GL, ZBe, LM) and 2nd Department of Medicine, Thrombosis and Hemostasis Division (ZBo) and Department of Biophysics and Cell Biology (GV) and Department of Clinical Biochemistry and Molecular Pathology (JK), University of Debrecen, Medical and Health Science Center, Debrecen, Hungary; Amalia Biron Research Institute of Thrombosis and Hemostasis, The Chaim Sheba Medical Center, Tel-Hashomer, Israel (NR, HH)
Correspondence: László Muszbek, MD, PhD, Clinical Research Center, University of Debrecen, Medical and Health Science Center, PO Box 40, Debrecen 4012, Hungary. E-mail: muszbek{at}med.unideb.hu
In the platelets of a type II Glanzmann thrombasthenia patient, the amount of glycoprotein (GP) IIb and IIIa was significantly reduced. Three novel mutations were identified in the GPIIb gene (c.440C
G/p.Leu116Val, c.1772_1773insG/p.Asp560 GlyfsX16 and c.2438C
A/p.His782Asn). p.Leu116Val did not represent a causative mutation. The c.1772_1773insG mutation resulted in an early stop codon and nonsense mediated decay of mRNA. When expressed in transfected BHK cells, the truncated protein was unable to form complex with GPIIIa. The p.His782Asn mutation compromised transport of the pro-GPIIb/IIIa complex from the endoplasmic reticulum to the Golgi, hindering its maturation and surface expression.
Key words: fibrinogen receptor, Glanzmann thrombasthenia, glycoprotein IIb mutations.
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |